Heron Therapeutics, Inc. (0J4V.L)
| Previous close | 2.8370 |
| Open | 3.1020 |
| Bid | 0.0000 x N/A |
| Ask | 0.0000 x N/A |
| Day's range | 3.1020 - 3.1020 |
| 52-week range | 3.1020 - 3.1020 |
| Volume | |
| Avg. volume | N/A |
| Market cap | 247.131M |
| Beta (5Y monthly) | 1.39 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -2.2930 |
| Earnings date | 08 Aug 2022 - 12 Aug 2022 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | N/A |
- Zacks
Heron Therapeutics (HRTX) Reports Q1 Loss, Tops Revenue Estimates
Heron Therapeutics (HRTX) delivered earnings and revenue surprises of -40% and 6.62%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
- Motley Fool
Up 1,000% in 5 Years? These Healthcare Stocks Could Pull It Off.
Patrick Bafuma is bullish on Legend Biotech (NASDAQ: LEGN) and thinks it might be worth $55 billion by 2027. George Budwell believes his pick, Heron Therapeutics (NASDAQ: HRTX), could jump 1,000% in that time frame. Patrick Bafuma (Legend Biotech): Lost amid the recent market doldrums has been some incredible news.
- Motley Fool
Why Heron Therapeutics Stock Is Getting Hammered Today
Shares of the small-cap biotech Heron Therapeutics (NASDAQ: HRTX) are down by a noteworthy 19.2% as of 2:48 p.m. ET Tuesday afternoon. The lack of commercial momentum for Heron's non-opioid painkiller Zynrelef appears to be the biggest concern for shareholders today. Heron has been one of the most heavily shorted stocks on the Nasdaq stock exchange for quite a while now.
